2022, FDA Approval, Pharmacokinetics and Protein Expression

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

2022

FDA Approval

Pharmacokinetics

Protein Expression

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Alta Sciences

APRIL 17, 2024

According to a 2022 article published in Molecular Psychiatry, treatment resistance affects 20 to 60% of patients with psychiatric disorders. They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression.

Drug Development

Drug Development Treatment FDA Approval Drugs

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

The Pharma Data

APRIL 8, 2021

We expect data from the studies in 2022. SMN protein is found throughout the body and is critical for maintaining healthy motor neurons and movement. Food and Drug Administration (FDA) approved EVRYSDI for the treatment of SMA in adults and children 2 months of age and older. Huntington’s Disease (HD).

Clinical Trials

Clinical Trials Trials Disease Nurses

Drug Discovery Digest

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

Stay Connected